stella
beta
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity — Stella
Home
/
Multiple Sclerosis (MS) - Relapsing-remitting
/
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
View on ClinicalTrials.gov
Recruiting
Back to Multiple Sclerosis (MS) - Relapsing-remitting trials
Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(2 sites)
France
CHU de Nice, Nice
CHU de Nîmes, Nîmes